Navigation Links
Cepheid Announces Symposium Program for 2009 Association for Professionals in Infection Control (APIC) Annual Conference
Date:6/4/2009

SUNNYVALE, Calif., June 4 /PRNewswire-FirstCall/ --- Cepheid (Nasdaq: CPHD) today announced speaker and program highlights for its symposium, "On-Demand HAI Testing: Good Medicine and Good Business," which the company will host at the 2009 Association for Professionals in Infection Control (APIC) annual conference, taking place in Fort Lauderdale, Florida, June 7th - 10th. Cepheid's GeneXpert(R) Systems and menu of molecular diagnostic tests will be on display in booth #906 on the exhibition floor.

"Management and prevention of Healthcare Associated Infections (HAIs) is a shared responsibility that includes the entire healthcare industry," said Sandra Finley, Cepheid's Vice President of Marketing. "We are pleased to present industry experts who will discuss the importance of reducing and eliminating HAI infections and the operational benefits that these investments bring in quality improvements, patient outcomes, and hospital throughput efficiencies."

The symposium, "On-Demand HAI Testing: Good Medicine and Good Business," is scheduled for Wednesday, June 10, 2009 from 11:30 a.m. to 1:30 p.m. EST. Interested parties, unable to attend the APIC conference, are invited to listen to the event live via webcast. To access the live webcast, please register through Cepheid's website at www.cepheid.com/events at least 15 minutes before the scheduled start time to download any necessary audio or plug-in software. APIC attendees can register to attend this exhibitor-sponsored symposium while at the conference.

The scheduled presenters are:

    Jorge P. Parada, MD, MPH
    Associate Professor
    Medical Director Infection Control Program
    Researcher Associate, Infectious Diseases and Immunology Institute (inDII)
    Stritch School of Medicine Loyola University Chicago

    William J. Ward, Jr., MBA
    Associate Professor
    Director, MHS Degree in Health Finance and Management
    Sommer Scholars Program Faculty Director
    Johns Hopkins Bloomberg School of Public Health

    Fred C. Tenover, Ph.D., D (ABMM)
    Senior Director, Scientific Affairs, Cepheid
    Adjunct Professor of Epidemiology, Rollins School
    of Public Health, Emory University, Atlanta, GA

Healthcare-associated infections exact a significant toll on human life, and are among the top ten leading causes of death in the United States. Recent reports estimate hospital stays for Methicillin-resistant Staphylococcus aureus (MRSA) infection have more than tripled since 2000 and represent $20 billion in excess healthcare costs each year. Similarly, Clostridium difficile infections have been increasing in incidence and severity, and have become a substantive and growing burden in hospitalized patients, prompting the need for earlier and accurate detection.

About Cepheid

Based in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is an on-demand molecular diagnostics company that develops, manufactures, and markets fully-integrated systems and tests for genetic analysis in the clinical, industrial and biothreat markets. The company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The company's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market. See http://www.cepheid.com for more information.

    CONTACTS:
    For Media Inquiries:                   For Cepheid Investor Inquiries:
    --------------------                   -------------------------------
    Jared Tipton                           Jacquie Ross
    Cepheid Corporate Communications       Cepheid Investor Relations
    408-400-8377                           408-400-8329
    jared.tipton@cepheid.com               investor.relations@cepheid.com


'/>"/>
SOURCE Cepheid
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cepheid to Present at ThinkEquity Partners 5th Annual Growth Conference
2. Cepheid Schedules Teleconference and Webcast for Third Quarter 2007 Results
3. Cepheid and Broadlane Sign Group Purchasing Contract for GeneXpert(R) Systems and Xpert(TM) Molecular Diagnostic Tests, Including Xpert MRSA
4. Cepheid to Present at the Needham Tenth Annual Growth Stock Conference
5. Cepheid Comments on Study Regarding MRSA Surveillance Reported in the Journal of the American Medical Association
6. Cepheid Selected as Vendor of Choice by Connecticut Hospital Association Shared Services Program for Molecular MRSA Surveillance Testing
7. Cepheid Reports Record Revenue of $44.8 Million
8. Cepheid Signs Group Purchasing Contract With Premier Healthcare Alliance, One of the Largest U.S. Group Purchasing Organizations
9. Cepheid Launches First On-Demand Molecular Diagnostic Test for Clostridium Difficile Into European Market
10. Cepheid Receives Health Canada License for First Molecular Diagnostic Test for MRSA and S. aureus Soft Tissue Infections
11. Cepheid Reports Fourth Quarter and Full Year 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... , ... December 04, 2016 , ... ... major cosmetic surgery can now take advantage of a cosmetic procedure known as ... rejuvenation treatment that reduces the appearance of age spots, fine lines, uneven ...
(Date:12/4/2016)... ... December 04, 2016 , ... Responsible dental care hinges ... brush properly to achieve optimal results. This important necessity inspired an inventor from Las ... a way to ensure that people break or avoid bad techniques of brushing the ...
(Date:12/2/2016)... ... ... Lori G. Cohen and Sara K. Thompson , shareholders in global ... Institute’s 21st Drug & Medical Device Litigation Conference , taking place in New York ... who chairs the firm’s Pharmaceutical, Medical Device & Health Care Litigation Practice and the ...
(Date:12/2/2016)... ... December 02, 2016 , ... On Dec. 2, 2016, CURE® magazine will host ... honoring the 2016 MPN Heroes—eight individuals who have made a difference in the field ... the standard of care, demonstrating leadership within the MPN community and/or a commitment to ...
(Date:12/2/2016)... Dothan, AL (PRWEB) , ... December 02, 2016 ... ... leaders from across the Dothan-Wiregrass Area in Alabama are expected to attend the ... Mike Schmitz, will help provide scholarship funds for area students and operating support ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , Dec. 5, 2016 ... hydroxyurea (HU) in Complete Hematologic Response (CHR) ... ropeginterferon alfa-2b versus HU AOP will submit ... CONTINUATION-PV to obtain European marketing authorization in the coming months ... the FDA as it seeks approval for commercialization in the ...
(Date:12/4/2016)... 2016 Sickle cell disease (SCD) is an ... cells that get stuck in veins and block blood ... and complications leading to death. Each year, approximately 300,000 ... most of them lack access to comprehensive care or ... therapy for SCD, a pill called hydroxyurea approved more ...
(Date:12/2/2016)... SILVER SPRING, Md. , Dec. 2, 2016 /PRNewswire-USNewswire/ ... a new indication for Jardiance (empagliflozin) to reduce the ... 2 diabetes mellitus and cardiovascular disease. ... adults with type 2 diabetes mellitus," said Jean-Marc ... Metabolism and Endocrinology Products in FDA,s Center for Drug ...
Breaking Medicine Technology: